Article
Medicine, General & Internal
Yi-Han Zuo, Wei-Na Gao, Ya-Jia Xie, Sheng-Yong Yang, Jin-Tai Zhou, Hai-Hai Liang, Xing-Xing Fan
Summary: PKC delta is identified as a critical factor in the non-inflamed tumor microenvironment (TME) of EGFR-mutated lung cancer. Inhibition of PKC delta enhances the infiltration of immune cells into tumors and increases the sensitivity of tumors to immune checkpoint blockade therapy.
Review
Immunology
Daoan Cheng, Kele Ge, Xue Yao, Banglu Wang, Rui Chen, Weiqing Zhao, Cheng Fang, Mei Ji
Summary: This study comprehensively reviews the mechanisms of tumor-associated macrophages (TAMs) in mediating resistance to epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) in the lung cancer microenvironment and discusses the potential efficacy of combining EGFR-TKIs with targeted TAMs therapy. The study suggests that combining EGFR-TKIs with TAMs targeting may have a certain extent of improvement in the prognosis of lung cancer patients with EGFR mutation.
FRONTIERS IN IMMUNOLOGY
(2023)
Review
Immunology
Ding-Yu Rao, De-Fa Huang, Mao-Yan Si, Hua Lu, Zhi-Xian Tang, Zu-Xiong Zhang
Summary: As an important mediator of information transfer between cells, exosomes play a unique role in regulating tumor growth, supporting vascular proliferation, tumor invasion, and metastasis. Exosomes can be used as a potential tool for non-invasive liquid biopsy due to their presence in various body fluids. This study reviews the role of exosomes in liquid biopsy, tumor microenvironment formation, and epithelial-mesenchymal transition in non-small cell lung cancer (NSCLC). It also discusses the occurrence of EGFR+ exosomes and the role of exosomes and their contents in non-invasive detection and potential therapeutic targets in EGFR-mutated lung cancer.
FRONTIERS IN IMMUNOLOGY
(2023)
Article
Chemistry, Multidisciplinary
Mofei Huang, Donghai Xiong, Jing Pan, Qi Zhang, Shizuko Sei, Robert H. Shoemaker, Ronald A. Lubet, Luis M. Montuenga, Yian Wang, Barbara S. Slusher, Ming You
Summary: JHU083, an orally active glutamine antagonist, effectively targets EGFR-driven lung tumorigenesis by increasing T cell infiltration and reducing immune suppressive cells, enhancing the efficacy of EVax.
Article
Multidisciplinary Sciences
Bin Zhang, Shaowei Dong, Jian Wang, Tuxiong Huang, Pan Zhao, Jing Xu, Dongcheng Liu, Li Fu, Lingwei Wang, Guangsuo Wang, Chang Zou
Summary: By using 3D printed patient derived xenograft models, this study identifies a NOTCH mutation as a predictor of response to EGFR-TKI therapy in LUAD. The NOTCH4(Delta L12_16) mutation increases the occurrence in EGFR-TKI-sensitive patients and sensitizes EGFR-TKI-resistant LUAD cells to the drug. This is mediated by reduced localization of NOTCH4 and down-regulation of HES1 expression. Inhibition of the NOTCH4-HES1 pathway can reverse EGFR-TKI resistance.
NATURE COMMUNICATIONS
(2023)
Article
Oncology
Lei Yang, Yun-Ting He, Song Dong, Xue-Wu Wei, Zhi-Hong Chen, Bo Zhang, Wei-Dong Chen, Xiao-Rong Yang, Fen Wang, Xue-Meng Shang, Wen-Zhao Zhong, Yi-Long Wu, Qing Zhou
Summary: This study investigates the immune microenvironment of EGFR-mutant and EGFR wild-type lung adenocarcinomas (LUADs) using single-cell transcriptome sequencing and multiplex immunohistochemistry. The results show that EGFR-mutant LUAD lacks CD8(+) tissue-resident memory (TRM) cells and has less crosstalk between T cells and other cell types compared to EGFR wild-type LUAD. These findings contribute to a better understanding of the immune landscape of EGFR-mutant LUAD at the single-cell level and suggest that the lack of CD8(+) TRM cells may be a key factor in the suppressive TME of EGFR-mutant LUAD.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2022)
Article
Oncology
Meng Qiao, Fei Zhou, Xinyu Liu, Tao Jiang, Haowei Wang, Yijun Jia, Xuefei Li, Chao Zhao, Lei Cheng, Xiaoxia Chen, Shengxiang Ren, Hongcheng Liu, Caicun Zhou
Summary: Our study suggests that EGFR-mutated tumors have fewer cytotoxic and exhausted CD39(+)CD8(+)T cells. Due to low levels of IL-10, these cells cannot be reinvigorated by anti-PD-1(L1) treatment. However, IL-10 can induce CD39 expression and enhance CD8(+)T cell immunity in a CD39-dependent manner. In mouse models of EGFR-mutated lung cancer, combining recombinant IL-10 protein and PD-1 blockade can optimize antitumor effects. IL-10 may serve as a cytokine-based strategy to improve the efficacy of anti-PD-1(L1) treatment in EGFR-mutated tumors.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2022)
Review
Biochemistry & Molecular Biology
Clelia Madeddu, Clelia Donisi, Nicole Liscia, Eleonora Lai, Mario Scartozzi, Antonio Maccio
Summary: EGFR mutation is common in non-small cell lung cancer (NSCLC), affecting the tumor microenvironment and immune response. EGFR activation increases PD-L1 expression, inhibiting T cell immune function. EGFR-TKIs enhance antigen presentation and boost immune cell levels while decreasing PD-L1 expression. Combination therapy may have synergistic effects, but EGFR signaling can create an immunosuppressive TME, requiring targeted approaches.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
Article
Oncology
Gang Xiao, Lifeng Li, Guilong Tanzhu, Zhiyuan Liu, Xuan Gao, Xin Wan, Desheng Xiao, Liu Chen, Xuefeng Xia, Rongrong Zhou
Summary: This study found that lung adenocarcinomas (LUAD) with EGFR-positive and ALK-positive had a suppressive tumor immune microenvironment (TIME) and were less responsive to immunotherapy. The TIME in patients with EGFR/ALK-positive LUAD brain metastases (BMs) was different from that in primary lung cancer. Evaluating the immune characteristics of LUAD BMs is important for clinical treatment.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2023)
Review
Biology
Siavash Mansouri, Daniel Heylmann, Thorsten Stiewe, Michael Kracht, Rajkumar Savai
Summary: Lung cancer classification and treatment have been revolutionized by advances in understanding driver mutations and the introduction of tumor microenvironment (TME)-associated immune checkpoint inhibitors. However, many patients develop resistance to these therapies due to specific driver mutations that favor an immunosuppressive TME phenotype. Clinical studies investigating the crosstalk between driver mutations and the TME immune profile hold promise for better treatment choices and personalized medicine.
Article
Multidisciplinary Sciences
Mari Tone, Kota Iwahori, Takayuki Shiroyama, Shinji Futami, Yujiro Naito, Kiyoharu Fukushima, Kotaro Miyake, Shohei Koyama, Haruhiko Hirata, Izumi Nagatomo, Hisashi Wada, Yoshito Takeda, Atsushi Kumanogoh
Summary: Minocycline administration in NSCLC patients treated with first-line EGFR-TKIs was found to correlate with longer PFS and OS, independent of skin rash. This retrospective analysis suggests that minocycline may have a positive impact on the treatment outcomes of EGFR-mutant NSCLC patients.
SCIENTIFIC REPORTS
(2023)
Letter
Oncology
Si-Yang Maggie Liu, Cunte Chen, Yi-Kai Zhang, Wen-Zhao Zhong, Yi-Long Wu, Si-Yang Liu, Yangqiu Li
Summary: This study identified specific TCR sequences that can predict prognosis and favorable outcomes in EGFR-mutant NSCLC patients treated with adjuvant EGFR-TKI.
BIOMARKER RESEARCH
(2023)
Article
Medicine, General & Internal
Yiqian Jiang, Leyi Shou, Qingmin Guo, Yanhong Bao, Xiaoping Xu, Suhong An, Jianfeng Lu
Summary: This case report discusses a patient who developed resistance to EGFR-TKIs due to SCLC transformation, emphasizing the importance of repeat biopsy for drug resistance and the potential usefulness of serum neuron-specific enolase levels in early detection of SCLC transformation.
Article
Oncology
Takashi Ito, Hiromi Nagashima, Masachika Akiyama, Yu Utsumi, Hideomi Sato, Shinji Chiba, Mayu Sugai, Kenji Ube, Yoshiaki Mori, Kana Watanabe, Tatsuro Fukuhara, Makoto Maemondo
Summary: EGFR-mutated NSCLC patients with L858R mutation are more likely to respond well to ICI treatment. The occurrence of T790M resistance mutation before ICI treatment did not differ significantly between different response groups. Patients with shorter duration of EGFR-TKI pretreatment are more likely to respond well to ICI treatment.
Article
Oncology
Si-Yu Lei, Hai-Yan Xu, Hong-Shuai Li, Ya-Ning Yang, Fei Xu, Jun-Ling Li, Zhi-Jie Wang, Pu-Yuan Xing, Xue-Zhi Hao, Yan Wang
Summary: This retrospective study found that programmed death-ligand 1 (PD-L1) expression influences the efficacy of epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) in EGFR-mutant non-small cell lung cancer (NSCLC) patients. Higher PD-L1 expression is associated with shorter progression-free survival (PFS). Additionally, combined use of TP53 and PD-L1 can identify subgroups with divergent benefits from EGFR-TKIs.
Article
Oncology
Yijun Jia, Xuefei Li, Chao Zhao, Tao Jiang, Sha Zhao, Limin Zhang, Xiaozhen Liu, Jinpeng Shi, Meng Qiao, Jiawei Luo, Sangtian Liu, Ruoshuang Han, Xiaoxia Chen, Caicun Zhou
Article
Oncology
Tong Wu, Fei Zhou, Adiilah K. Soodeen-Lalloo, Xing Yang, Yingran Shen, Xi Ding, Jinpeng Shi, Jie Dai, Jingyun Shi
CLINICAL LUNG CANCER
(2019)
Article
Oncology
Sha Zhao, Xuefei Li, Chao Zhao, Tao Jiang, Yijun Jia, Jinpeng Shi, Yayi He, Jiayu Li, Fei Zhou, Guanghui Gao, Wei Li, Xiaoxia Chen, Chunxia Su, Shengxiang Ren, Caicun Zhou
Article
Oncology
Sha Zhao, Shengxiang Ren, Tao Jiang, Bo Zhu, Xuefei Li, Chao Zhao, Yijun Jia, Jinpeng Shi, Limin Zhang, Xiaozhen Liu, Meng Qiao, Xiaoxia Chen, Chunxia Su, Hui Yu, Caicun Zhou, Jun Zhang, D. Ross Camidge, Fred R. Hirsch
CANCER IMMUNOLOGY RESEARCH
(2019)
Article
Biotechnology & Applied Microbiology
Limin Zhang, Yan Wang, Chao Zhao, Jinpeng Shi, Sha Zhao, Xiaozhen Liu, Yijun Jia, Tao Zhu, Tao Jiang, Xuefei Li, Caicun Zhou
ONCOTARGETS AND THERAPY
(2019)
Article
Oncology
Tao Jiang, Jinpeng Shi, Zhengwei Dong, Likun Hou, Chao Zhao, Xuefei Li, Beibei Mao, Wei Zhu, Xianchao Guo, Henghui Zhang, Ji He, Xiaoxia Chen, Chunxia Su, Shengxiang Ren, Chunyan Wu, Caicun Zhou
JOURNAL OF HEMATOLOGY & ONCOLOGY
(2019)
Article
Cell Biology
Xiaozhen Liu, Tao Jiang, Xuefei Li, Chao Zhao, Jiayu Li, Fei Zhou, Limin Zhang, Sha Zhao, Yijun Jia, Jinpeng Shi, Guanghui Gao, Wei Li, Jing Zhao, Xiaoxia Chen, Chunxia Su, Shengxiang Ren, Caicun Zhou
JOURNAL OF CELLULAR AND MOLECULAR MEDICINE
(2020)
Article
Oncology
Ruoshuang Han, Yijun Jia, Xuefei Li, Chao Zhao, Sha Zhao, Sangtian Liu, Yiwei Liu, Donglai Chen, Qian Zhang, Xiaozhen Liu, Jinpeng Shi, Jiayu Li, Caicun Zhou
Summary: The study suggests that concurrent use of metformin could be beneficial in EGFR-mutant NSCLC patients treated with either first-line EGFR-TKIs or second-line osimertinib. In vitro experiments demonstrated synergistic interaction between metformin and gefitinib or osimertinib, and enhanced apoptosis in TKI-resistant cells. Retrospective cohort analysis showed higher response rates and longer survival in patients using metformin, indicating its potential in overcoming EGFR-TKI resistance.
TRANSLATIONAL LUNG CANCER RESEARCH
(2021)
Article
Oncology
Jinpeng Shi, Jiayu Li, Qi Wang, Xiaomin Cheng, He Du, Ruoshuang Han, Xuefei Li, Chao Zhao, Guanghui Gao, Yayi He, Xiaoxia Chen, Chunxia Su, Shengxiang Ren, Fengying Wu, Zhemin Zhang, Caicun Zhou
Summary: Anti-PD-1/PD-L1 immunotherapy has shown potential risks in the treatment of lung cancer, but it is relatively safe and effective in patients previously treated for latent TB. Screening for TB before immunotherapy and careful monitoring of adverse events in lung cancer patients with active TB infection are strongly recommended.
TRANSLATIONAL LUNG CANCER RESEARCH
(2021)
Article
Health Care Sciences & Services
Yongwei Xu, Jinpeng Shi, Shuchang Xu, Chunli Cui
Summary: This case report describes a 66-year-old man with primary nephrotic syndrome complicated by membranous nephropathy-induced chylothorax. Treatment of the chylothorax included chest tube drainage, enoxaparin injection, anti-inflammatory agents, and diuretics. Following treatment, the patient's pleural effusion decreased and the chyle cleared gradually.
ANNALS OF PALLIATIVE MEDICINE
(2022)
Article
Genetics & Heredity
Zhuoran Tang, Qi Wang, Peixin Chen, Haoyue Guo, Jinpeng Shi, Yingying Pan, Chunyu Li, Caicun Zhou
Summary: This study identified neutrophil-specific lncRNA with prognostic significance in squamous cell carcinoma and lung adenocarcinoma using a machine learning-based computing framework. The identified lncRNA, named TANlncSig, was able to independently distinguish between better and worse survival outcomes in different patient datasets. Functional assessment of TANlncSig showed it is a marker of myeloid cell infiltration into tumor infiltration and myeloid cells play a role in inhibiting the anti-tumor immune response.
FRONTIERS IN GENETICS
(2022)
Article
Engineering, Electrical & Electronic
Yingpei Liu, Jiangyu Hu, Jinpeng Shi, Bochao Yang
Summary: Due to the lack of grid inertia caused by the increasing penetration of renewable energy sources, an adaptive virtual inertial frequency control (AVIFC) strategy is proposed for multi-terminal dc (MMC-MTDC) transmission system to address the reduced ability of the system to withstand disturbance. The strategy adjusts the virtual inertia coefficient based on frequency variation characteristics in different response stages. Furthermore, an adaptive droop control (ADC) strategy is studied to achieve coordinated power sharing and maintain stability of DC voltage after disturbance in weak AC systems.
INTERNATIONAL JOURNAL OF ELECTRICAL POWER & ENERGY SYSTEMS
(2023)
Article
Medicine, General & Internal
Wen-hong Wu, Yong-hong Feng, Chun-yan Min, Shao-wei Zhou, Zi-dan Chen, Li-min Huang, Wen-lan Yang, Guang-hong Yang, Jun Li, Jin Shi, Hua Quan, Ling Mao
Summary: A retrospective cohort study on 89 artificial stone workers in Shanghai, China found that the use of tetrandrine can control and delay the progression of silicosis fibrosis. This treatment also improves chest HRCT imaging and pulmonary function.
FRONTIERS IN MEDICINE
(2023)
Article
Remote Sensing
Wentao Tao, Junjie Ma, Jinpeng Shi, Wenbing Lv, Mingyue Zhao, Ling Zheng, Linsheng Huang, Shizhuang Weng
Summary: This study introduces a dual-strategy semi-supervised learning method for recognizing tomato leaf diseases when labelled images are insufficient. By attaching an extra classifier to the generative adversarial network and integrating unlabelled images, the method achieves more accurate disease recognition.
INTERNATIONAL JOURNAL OF REMOTE SENSING
(2022)
Article
Oncology
Yuxin Liu, Swati Bhardwaj, Keith Sigel, John Winters, Joseph Terlizzi, Michael M. Gaisa
Summary: This study investigated the prevalence and severity of anal HPV disease among MSM LWH under the age of 35, finding a high prevalence of HPV infection and precancer but no cases of invasive anal cancer. This supports the adoption of age-based anal cancer screening for this population.
INTERNATIONAL JOURNAL OF CANCER
(2024)
Correction
Oncology
J. Gu, S. Xie, S. Wang
INTERNATIONAL JOURNAL OF CANCER
(2024)